A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future

References

• Touat M, Opatowski M, Brun-Buisson C, et al., A payer perspective of the hospital inpatient additional care costs of antimicrobial resistance in France: a matched case-control study. Appl Health Econ Health Policy. 2019;17(3):381–389.
   PubMed Web of Science ®Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Ikuta KS, Sharara F; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.
   PubMed Web of Science ®Google Scholar
• Review on Antimicrobial Resistance [Internet]. Antimicrobial resistance: tackling a crisis for the health and wealth of nations; 2014 December [cited 2022 Aug 29]; [20 p.]. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• World Health Organization. [Internet]. Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. [cited 2022 Aug 29]; [ about 2 screens]. Available from: https://www.who.int/publications/i/item/9789240036024
   Google Scholar
• Kållberg C, Salvesen Blix H, Laxminarayan R. Challenges in antibiotic R&D calling for a global strategy considering both short- and long-term solutions. ACS Infect Dis. 2019;5(8):1265–1268.
   PubMed Web of Science ®Google Scholar
• Jackson N, Czaplewski L, Piddock LJV. Discovery and development of new antibacterial drugs: learning from experience? J Antimicrob Chemother. 2018;73(6):1452–1459.
   PubMed Web of Science ®Google Scholar
• Årdal C, Baraldi E, Theuretzbacher U, et al. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. J Pharm Policy Pract. 2018;11(1):8.
   PubMedGoogle Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892.
   PubMed Web of Science ®Google Scholar
• Cama J, Leszczynski R, Tang PK, et al. To push or to pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority. ACS Infect Dis. 2021;7(8):2029–2042.
   PubMed Web of Science ®Google Scholar
• Duval RE, Grare M, Demoré B. Fight against antimicrobial resistance: we always need new antibacterials but for right bacteria. Molecules. 2019;24(17):3152.
   PubMed Web of Science ®Google Scholar
• Outterson K, Orubu ESF, Rex J, et al., Patient access in fourteen high-income countries to new antibacterials approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020. Clin Infect Dis. 2022;74(7):1183–1190.
   PubMed Web of Science ®Google Scholar
• Boyd NK, Teng C, Frei CR. Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing. Front Cell Infect Microbiol. 2021;11:684515.
   PubMed Web of Science ®Google Scholar
• Federal Ministry of Health. Breaking through the wall: a call for concerted action on antibiotics research and development; Berlin: Federal Ministry of Health; 2017. [cited 2022 Aug 29]; [84 p.]. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf
   Google Scholar
• Littmann J, Viens AM. The ethical significance of antimicrobial resistance. Public Health Ethics. 2015;8(3):209–224.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40.
   PubMed Web of Science ®Google Scholar
• Brown ED. Is the GAIN Act a turning point in new antibiotic discovery? Can J Microbiol. 2013;59(3):153–156.
   PubMed Web of Science ®Google Scholar
• Yagisawa M. [Current status and prospective of antibacterial agents regarding countermeasure against antimicrobial resistance (AMR)]. Journal of Healthcare-associated Infection. 2019,12:55–71.Japanese.
   Google Scholar
• Kostyanev T, Bonten MJ, O’Brien S, et al. The Innovative Medicines Initiative’s New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother. 2016;71(2):290–295.
   PubMed Web of Science ®Google Scholar
• Balasegaram M, Piddock LJV. The Global Antibiotic Research and Development Partnership (GARDP) not-for-profit model of antibiotic development. ACS Infect Dis. 2020;6(6):1295–1298.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Guidance document: antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases; 2017 August [cited 2022 Aug 29]; [ about 2 screens]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases
   Google Scholar
• European Medicines Agency [Internet]. European Medicines Agency. 1995-2022 Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections; 2013 October [cited 2022 Aug 29]; [20 p.]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Guideline for clinical evaluation of antibacterial drugs (October 23, 2017, PSEHB/PED Notification No. 1023-3). Provisional Translation (as of 2020 March) [cited 2022 Aug 29]; [88 p.]. Available from: https://www.pmda.go.jp/files/000234350.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. [Reference information regarding guideline for clinical evaluation of antibacterial drugs (October 23, 2017, Administrative Notice)]. [cited 2022 Aug 29]; [5 p]. Japanese. Available from: https://www.pmda.go.jp/files/000221066.pdf
   Google Scholar
• Ministry of Health, Labour and Welfare of Japan. [Guidelines for PK/PD evaluation of antibacterial agents (December 25, 2015, ELD/PSEB Notification No. 1225-10)]. Jpn J Chemother. 2016;64(2):139–151. Japanese
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Report on clinical evaluation of antimicrobial agents for AMR, October 4, 2019 (provisional translation). [cited 2022 Aug 29]; [23 p.]. Available from: https://www.pmda.go.jp/files/000233507.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Tripartite meeting held between EMA, FDA and PMDA towards enhancing development for antibacterial agents. [cited 2022 Aug 29]; [ about 2 screens]. Available from: https://www.pmda.go.jp/english/int-activities/outline/0018.html
   Google Scholar
• Nambiar S, Cavaleri M, Sato J. Achieving regulatory alignment for anti-infective clinical trials. ACS Infect Dis. 2020;6(6):1308–1310.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. [Results of re-evaluation of prescription drugs, fiscal year 2004, part 3 (September 30, 2004, PFSB Notification No. 0930002)]. [cited 2022 Aug 29]. Japanese. Available from: https://www.pmda.go.jp/files/000148071.pdf
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [Internet]. Efficacy Guidelines. [cited 2022 Aug 29]; [ about 2 screens]. Available from: https://www.ich.org/page/efficacy-guidelines
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (September 28, 2007, Notification No. 0928010) [cited 2022 Aug 29]; [11 p.]. Available from: https://www.pmda.go.jp/files/000157900.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (reference cases. (Administrative Notice. 2012 Sept 5. cited 2022 Sept 5.12:]. (Administrative Notice. https://www.pmda.go.jp/files/000152969.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency [Internet]. Basic principles on global clinical trials (reference cases) (Administrative Notice, September 5, 2012). [cited 2022 Aug 29]; [12 p.]. Available at: https://www.pmda.go.jp/files/000152969.pdf
   Google Scholar
• Ushijima S, Matsumaru N, Tsukamoto K. Evaluation of drug lags in development initiation, new drug application and approval between Japan and the USA and the impact of local versus multi-regional clinical trials. Pharmaceut Med. 2021;35(4):253–260.
   PubMed Web of Science ®Google Scholar
• Ohmagari N. National Action Plan on Antimicrobial Resistance (AMR) 2016-2020 and relevant activities in Japan. Glob Health Med. 2019;1(2):71–77.
   PubMedGoogle Scholar
• World Health Organization. [Internet]. Japan: national action plan on antimicrobial resistance (AMR) 2016-2020; 2016 April. World Health Organization; 2022. [cited 2022 Aug 29]; [ about 2 screens]. Available from: https://www.who.int/publications/m/item/japan-national-action-plan-on-antimicrobial-resistance-(amr)
   Google Scholar
• Gu Y, Fujitomo Y, Ohmagari N. Outcomes and future prospect of Japan’s National Action Plan on Antimicrobial Resistance (2016-2020). Antibiotics (Basel). 2021;10(11):1293.
   PubMed Web of Science ®Google Scholar
• Japan Agency for Medical Research and Development [Internet]. About AMED. [cited 2022 Aug 29]; [about 2 screens]. Available from: https://www.amed.go.jp/en/aboutus/index.html
   Google Scholar
• Japan Agency for Medical Research and Development [Internet]. Japanese Initiative for Progress of Research on Infectious Disease for global Epidemic (J-PRIDE); 2019 Jul 12 [cited 2022 Aug 29]; [about 3 screens]. Available from: https://www.amed.go.jp/en/program/list/01/06/005.html
   Google Scholar
• Konno Y, Nagaoka S, Kimura I, et al. New world feline APOBEC3 potently controls inter-genus lentiviral transmission. Retrovirology. 2018;15(1):31.
   PubMedGoogle Scholar
• Mi-Ichi F, Yoshida H. Unique features of Entamoeba sulfur metabolism; compartmentalization, physiological roles of terminal products, evolution and pharmaceutical exploitation. Int J Mol Sci. 2019;20(19):4679.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Aiba Y, Tan XE, et al. Complete genome sequencing of three human clinical isolates of Staphylococcus caprae reveals virulence factors similar to those of S. epidermidis and S. capitis. BMC Genomics. 2018;19(1):810.
   PubMedGoogle Scholar
• Japan Agency for Medical Research and Development [Internet]. CiCLE: cyclic innovation for clinical empowerment; 2018. [cited 2022 Aug 29]; [ about 3 screens]. Available from: https://www.amed.go.jp/en/program/list/17/01/001.html
   Google Scholar
• Nagase H, Saitoh A. Research and development of κ opioid receptor agonists and δ opioid receptor agonists. Pharmacol Ther. 2020;205:107427.
   PubMed Web of Science ®Google Scholar
• Shimoyama A, Di Lorenzo F, Yamaura H, et al. Lipopolysaccharide from gut-associated lymphoid-tissue-resident Alcaligenes faecalis: complete structure determination and chemical synthesis of its lipid A. Angew Chem Int Ed Engl. 2021;60(18):10023–10031.
   PubMed Web of Science ®Google Scholar
• Yagishita S, Kato K, Takahashi M, et al. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci. 2021;112(6):2454–2466.
   PubMed Web of Science ®Google Scholar
• Japan Agency for Medical Research and Development [Internet]. Research Program on Emerging and Re-emerging Infectious Diseases; 2020 Oct 20 [cited 2022 Aug 29]; [ about 3 screens]. Available from: https://www.amed.go.jp/en/program/list/11/02/002.html
   Google Scholar
• Japan Agency for Medical Research and Development [Internet]. AMED support for R&D on the novel coronavirus disease (COVID-19) (summary); 2020 Nov 20 [cited 2022 Aug 29]; [ about 10 screens]. Available from: https://www.amed.go.jp/en/news/topics/covid-19.html
   Google Scholar
• Japan Agency for Medical Research and Development [Internet]. Joint Programming Initiative on Antimicrobial Resistance (JPIAMR); 2017 Apr 7 [cited 2022 Aug 29; [ about 3 screens]. Available from: https://www.amed.go.jp/en/aboutus/collaboration/jpiamr.html
   Google Scholar
• Tanaka M, Idei M, Sakaguchi H, et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021;87(10):4027–4035.
   PubMed Web of Science ®Google Scholar
• Matsushita S, Tachibana K, Kusakabe T, et al. Overview of the premarketing and postmarketing requirements for drugs granted Japanese conditional marketing approval. Clin Transl Sci. 2021;14(3):806–811.
   PubMed Web of Science ®Google Scholar
• e-Gov Japanese law portal [Internet]. [Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices]. Act No. 145 of 1960, Amendment of Act No. 63 of 2019. [cited 2022 Aug 29]; [about 120 screens]. Japanese. Available from: https://elaws.e-gov.go.jp/document?lawid=335AC0000000145
   Google Scholar
• Maeda H. Japan’s special approval for emergency system during the COVID-19 pandemic. Clin Pharmacol Ther. 2022;111(3):551–558.
   PubMed Web of Science ®Google Scholar
• Prime Minister’s Office of Japan [Internet]. Health/medical strategy promotion expert committee (30th). [cited 2022 Aug 29]; [ about 2 screens]. Japanese. Available from: https://www.kantei.go.jp/jp/singi/kenkouiryou/tyousakai/dai30/gijisidai.html
   Google Scholar
• Ministry of Health, Labour and Welfare of Japan [Internet]. Health science council (Pharmaceuticals and medical devices system subcommittee). [cited 2022 Aug 29]; [about 3 screens]. Japanese. Available from: https://www.mhlw.go.jp/stf/shingi/shingi-kousei_430263.html
   Google Scholar
• Ueda M, Tanimoto T, Murayama A, et al. Japan’s drug regulation during the COVID-19 pandemic: lessons from a case study of favipiravir. Clin Pharmacol Ther. 2022;111(3):545–547.
   PubMed Web of Science ®Google Scholar
• Arima Y, Kanou K, Arashiro T, et al. Epidemiology of coronavirus disease 2019 in Japan: descriptive findings and lessons learned through surveillance during the first three waves. Jpn Med Assoc J. 2021;4(3):198–206.
   Google Scholar
• Uddin S, Imam T, Khushi M, et al. How did socio-demographic status and personal attributes influence compliance to COVID-19 preventive behaviours during the early outbreak in Japan? Lessons for pandemic management. Pers Individ Dif. 2021;175:110692.
   Google Scholar
• Shimizu K, Negita M. Lessons learned from Japan’s response to the first wave of COVID-19: a content analysis. Healthcare (Basel). 2020;8(4):426.
   PubMedGoogle Scholar
• Saito T, Muto K, Tanaka M, et al. Proactive engagement of the expert meeting in managing the early phase of the COVID-19 epidemic, Japan, February-June 2020. Emerg Infect Dis. 2021;27(10):1–9.
   PubMedGoogle Scholar
• Miethke M, Pieroni M, Weber T, et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 2021;5(10):726–749.
   PubMed Web of Science ®Google Scholar
• Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797–807.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Guidance document: adaptive designs for clinical trials of drugs and biologics guidance for industry. 2019 December [cited 2022 Aug 29]; [ about 2 screens]. about 2 screens: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry
   Google Scholar
• The RECOVERY Collaborative GroupHorby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial ConsortiumPan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Adaptive COVID-19 Treatment Trial (ACTT). [cited 2022 Aug 29]; [about 13 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04280705
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — Final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Collins FS, Stoffels P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455–2457.
   PubMed Web of Science ®Google Scholar
• REMAP-CAP: a randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia [Internet]. REMAP-CAP. [cited 2022 Aug 29]. Available from: https://www.remapcap.org/
   Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Kamata K, Jindai K, Ichihara N, et al. Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan. J Intensive Care. 2021;9(1):34.
   PubMed Web of Science ®Google Scholar
• Tsuruya N, Kawashima T, Shiozuka M, et al. Academia-industry cooperation in the medical field: matching opportunities in Japan. Clin Ther. 2018;40(11):1807–1812.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Austin C, Sato N, et al. The Global academic research organization network: data sharing to cure diseases and enable learning health systems. Learn Health Syst. 2018;3(1):e10073.
   PubMed Web of Science ®Google Scholar
• AMR Action Fund [Internet]. AMR action fund. c2022. [cited 2022 Aug 29]. Available from 2022 Aug 29. https://www.amractionfund.com/
   Google Scholar
• Clancy CJ, Nguyen MH. Buying time: the AMR Action Fund and the state of antibiotic development in the United States 2020. Open Forum Infect Dis. 2020;7(11):ofaa464.
   PubMed Web of Science ®Google Scholar
• Onyeaka H, Al-Sharify ZT, Ghadhban MY, et al. A review on the advancements in the development of vaccines to combat coronavirus disease 2019. Clin Exp Vaccine Res. 2021;10(1):6–12.
   PubMed Web of Science ®Google Scholar
• Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot (Tokyo). 2016;69(2):73–88.
   PubMed Web of Science ®Google Scholar
• Innovative Medicines Initiative [Internet]. ND4BB: new drugs for bad bugs. [cited 2022 Aug 29]; [about 7 screens]. Available from: https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb
   Google Scholar
• CARB-X: combating antibiotic-resistant bacteria [Internet]. [cited 2022 Aug 29]. Available from: https://carb-x.org/
   Google Scholar
• US Department of Health and Human Services [Internet]. Biomedical advanced research and development authority. [cited 2022 Aug 29]; [ about 4 screens]. about 4 screens: https://www.phe.gov/about/barda/Pages/default.aspx
   Google Scholar
• Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health. 2013;9(1):58.
   PubMedGoogle Scholar
• Japan Pharmaceutical Manufacturers Association [Internet]; Yuasa A, Yoshida M, Tawaragi Y. Situation and issues of development of antimicrobial drugs in Japan and Europe and United States. [cited 2022 Aug 29]; [11 p.]. Available from: https://www.jpma.or.jp/english/globalhealth/infectious_diseases/amr/eki4g60000004bso-att/eplg5k000000067k.pdf
   Google Scholar
• GOV.UK [Internet]. G7 finance ministers’ statement on actions to support antibiotic development. [cited 2022 Aug 29]; [about 3 screens]. Available from: https://www.gov.uk/government/publications/g7-finance-ministers-statement-on-actions-to-support-antibiotic-development
   Google Scholar
• Japan Pharmaceutical Manufacturers Association [Internet]. Japan Pharmaceutical Manufacturers Association; c2006-2021. Recommendations on Antimicrobial Resistance (AMR) [cited 2022 Aug 29]; [about 2 screensAvailable from]: https://www.jpma.or.jp/english/globalhealth/infectious_diseases/amr/recommendations.html
   Google Scholar
• AMR Alliance Japan [Internet]. Our policy recommendations. [cited 2022 Aug 29]; [about 5 screens]. Available from: https://www.amralliancejapan.org/en/goals/
   Google Scholar
• Morikane K. Infection control in healthcare settings in Japan. J Epidemiol. 2012;22(2):86–90.
   PubMed Web of Science ®Google Scholar
• Prime Minister of Japan and His Cabinet [Internet]. The prime minister in action: headquarters for healthcare policy. (June 1, 2021). [cited 2022 Aug 29]; [about 2 screens]. Available from: https://japan.kantei.go.jp/99_suga/actions/202106/_00001.html
   Google Scholar
• Ministry of Health, Labour and Welfare of Japan [Internet]. Study group on ensuring the availability of drugs for infectious disease crisis. [cited 2022 Aug 29]; [about 2 screens]. Japanese. Available from: https://www.mhlw.go.jp/stf/shingi/other-kenkou_kansennsyokikitaiou.html
   Google Scholar
• World Health Organization [Internet]. Preparing for pandemics [cited 2022 Aug 29]; [about 2 screens]. Available from: https://www.who.int/westernpacific/activities/preparing-for-pandemics
   Google Scholar
• Lu J, Sheldenkar A, Lwin MO. A decade of antimicrobial resistance research in social science fields: a scientometric review. Antimicrob Resist Infect Control. 2020;9(1):178.
   PubMed Web of Science ®Google Scholar
• Itoh N, Akazawa N, Kanawaku E, et al. Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: an interrupted time-series analysis. PLoS One. 2022;17(1):e0263095.
   PubMed Web of Science ®Google Scholar
• Maeda M, Miyake T, Inose R, et al. Bibliometric analysis of pharmacist’s research on antimicrobial stewardship in Japan: an interrupted time series analysis on the implementation of the certification system for infection control pharmacists. J Pharm Health Care Sci. 2021;7(1):38.
   PubMed Web of Science ®Google Scholar
• Mukai S, Shigemura K, Yang YM, et al. Comparison between antimicrobial stewardship program and intervention by infection control team for managing antibiotic use in neurogenic bladder-related urinary tract infection patients: a retrospective chart audit. Am J Infect Control. 2022;50(6):668–672.
   PubMed Web of Science ®Google Scholar
• Uda A, Shigemura K, Kitagawa K, et al. Effect of antimicrobial stewardship on oral quinolone use and resistance patterns over 8 years (2013-2020). Antibiotics (Basel). 2021;10(11):1426.
   PubMed Web of Science ®Google Scholar
• Ntt D, Htl V, Nguyen CTK, et al. Community-based antibiotic access and use in six low-income and middle-income countries: a mixed-method approach. Lancet Glob Health. 2021;9(5):e610–e619.
   PubMed Web of Science ®Google Scholar